| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 29.49 | 0.09 (+0.31%) | 22.00 - 31.15 | 77.0 million (Above Avg) |
Market data as of 2:10PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 29.37 |
|---|---|
| Previous Close | 29.40 |
| Day's Range | 29.23 - 29.81 |
| Market Cap | 208.4B |
| Avg Volume (10 Day) | 96.7M |
| Price/Earnings (Trailing 12 Mo.) | 14.1x |
| Earnings Per Share (Trailing 12 Mo.) | 2.08 |
| Dividend Yield | 0.24 (3.26%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Pass |
|---|---|
| Room to increase dividends? | Pass |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Pass |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
InSite Vision Announces Joint Patent Infringement Lawsuit with Merck Against Mylan Pharmaceuticals
Business Wire - Monday 06/17/2013 8:30 AM ET
Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals
PR Newswire - Monday 06/17/2013 8:00 AM ET
Zoetis Set to Join S&P 500; First Horizon National to Join S&P MidCap 400; QLogic to Join S&P SmallCap 600
PR Newswire - Friday 06/14/2013 5:44 PM ET
Pfizer Obtains $2.15 Billion Settlement from Teva and Sun for Infringement of Protonix® Patent
Business Wire - Wednesday 06/12/2013 7:49 AM ET
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Business Wire - Thursday 06/06/2013 10:00 AM ET
Pfizer Chooses UnitedLex to Manage Document Review Services
Business Wire - Wednesday 06/05/2013 12:16 PM ET
Americans Believe Their Communities Are Ill-Prepared For Aging Population, New Survey Reveals; Survey Shows A Fear Of Getting Old Due To Health And Financial Concerns
Business Wire - Wednesday 06/05/2013 7:00 AM ET
UPM Pharmaceuticals® Purchases Pfizer Commercial Manufacturing site in Bristol, TN
PR Newswire - Wednesday 05/29/2013 9:45 AM ET
| PFE | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -13.16% | |
| Net Income Growth (1yr) | 61.75% | |
| Total Debt/Equity | 0.49 | |
| LT Debt/Equity | 0.38 | |
| Earnings Yield | 7.09% | |
| Price/Sales | 3.61 |
| Company | Last | Change |
|---|---|---|
| Novartis AG | 72.69 | -0.59% |
| Johnson & Johnson | 85.91 | -0.52% |
| Sanofi SA | 53.90 | -1.21% |
| Merck & Co Inc | 47.82 | +0.15% |
| GlaxoSmithKline PLC | 52.11 | -0.69% |
Data is delayed by at least 15 min.